ClinicalTrials.gg
CompletedNCT06717815Updated Sep 9, 2026

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

A Phase 1/2 interventional study of IPG11406 in Lupus Nephritis, sponsored by Nanjing Immunophage Biotech Co., Ltd. Completed at 17 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Enrollment
59th of 88
24 · median 51
Started
2025
with 18 others
Phase 1/2
10 of 96
6 open now
Registered
69th of 96
by date

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 59th largest by enrollment of the 88 interventional ones that give a count, is one of 19 that started in 2025, is one of 10 in phase 1/2, and was the 69th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

Read the detailed description

This is a multi-center, multi-dose phase Ib/IIa study to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis.

This study has two parts.In Part A1, there will be 3 dose groups, 20 mg bid (Cohort 1), 40 mg bid (Cohort 2), 80 mg bid (Cohort 3).In Cohorts 1 to 3, there will be 3-6 participants in each cohort.In Part A2, dose expansion will be conducted at the proposed recommended Phase 2 dose (RP2D). All subjects will be screened within 28 days before administration, and eligible subjects will be administered and observed for 28 days after screening. In this part, it is planned to recruit about 36 patients with nephritis.

After each cohort has completed the 28-day dosing and evaluation, the safety monitoring committee (SMC) will evaluate the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available PK data. Based on the evaluation results of safety and tolerability, the SMC will decide whether to administer the next dose group.Part A1 will determine the recommended Phase 2 dose (RP2D) and maximum tolerated dose (MTD) of IPG11406.

The design of Part B will be finalized based on the results of Part A.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Criteria for Inclusion and Exclusion \<Inclusion Criteria>

  1. Aged 18-70 years (inclusive), male or female.
  2. In line with the revised classification criteria of the American College of Rheumatology (ACR) 1997, adult subjects diagnosed with systemic lupus erythematosus prior to screening.
  3. Confirmed disease activity during screening: SLEDAI-2K score ≥6.
  4. The patient's 24-h urine protein-to-creatinine ratio (UPCR) is >0.5 g/g or 24-h urine protein is ≥0.5 g during the screening period, and the estimated (eGFR) calculated using the MDRD formula is ≥60 mL/min/1.73 m\^2.
  5. The patient's baseline blood IFN-γ level exceeded the (Part B only).
  6. Patients with baseline peripheral blood Th1/Th2 ratio ≥14 (Part B only).
  7. (1) Subjects who have not received induction therapy or have not received treatment in the past 2 months are allowed to be enrolled, but other treatments for systemic lupus erythematosus and lupus nephritis (including hormones, , hydroxychloroquine sulfate, and biologics) are not allowed to be added during the study and follow-up period except for the study treatment.

(2) Subjects are allowed to be receiving any of the following standard treatment regimens at the time of enrollment: 1) Oral prednisone (or equivalent) monotherapy: a. Treatment duration: ≥ 2 weeks prior to screening and have a stable dose for ≥ 2 weeks prior to enrollment; b. Dose requirements: maximum daily dose: 1 mg/kg/day; 2) Immunosuppressants: a. Permitted medications include: antimalarials, azathioprine, cyclophosphamide, mycophenolate mofetil/mycophenolic acid, methotrexate, cyclosporine A, and tacrolimus; b. Treatment duration: ≥ 12 weeks prior to screening and have a stable dose for ≥ 8 weeks prior to enrollment; c. Dose requirements: hydroxychloroquine ≤ 400 mg/day, azathioprine ≤ 100 mg/day, cyclophosphamide ≤ 800 mg/4 weeks, mycophenolate mofetil/mycophenolic acid ≤ 2 g/day, oral, subcutaneous (SC), or intramuscular methotrexate ≤ 15 mg/week, cyclosporine A ≤ 3 mg/kg/day, tacrolimus ≤ 3 mg/day; 3) Oral prednisone (or equivalent) monotherapy ± hydroxychloroquine sulfate ± ≥ one immunosuppressant a. The above requirements for treatment duration and dose stability of oral (OCS) and immunosuppressants should be met; b. The maximum daily/weekly dose of each drug in 1) and 2) should not be exceeded.

8.Female subjects are required to be non-pregnant and non-lactating during the trial.

9.Subjects who do not have a pregnancy plan, voluntarily take effective measures (see the Appendix for details), and have no sperm or egg donation plan from screening to 6 months after the end of the study.

The subject voluntarily participates in the study, is able to sign the form, and complies with the requirements on the informed consent form.

\<Exclusion Criteria>

  1. Pregnant and lactating women.
  2. Have participated in other clinical trials within 3 months before screening and/or are currently participating in other clinical trials (except for those who have not used the product).
  3. Active severe lupus nephritis with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m\^2 calculated using the MDRD formula.
  4. Severe neuropsychiatric SLE includes, but is not limited to, the following: seizures, new or worsening impaired level of consciousness, psychosis, delirium or confusional state, aseptic meningitis, ascending or transverse myelitis, chorea, cerebellar ataxia, mononeuritis multiplex, demyelinating syndromes, or any condition that prevents the subject from fully understanding the ICF.
  5. History or current diagnosis of non-SLE-associated vasculitis syndrome or overlap with other connective tissue diseases.
  6. Any active dermatologic disease other than SLE that may interfere with study assessments of SLE, including but not limited to psoriasis, dermatomyositis, systemic sclerosis, non-SLE cutaneous lupus manifestations (eg, cutaneous vascular disease, periungual telangiectasias, sclerodactyly, rheumatoid nodules, erythema multiforme, leg ulcers), or drug-induced lupus.
  7. Those who have had or are currently suffering from malignant tumors in the past 5 years (except for skin squamous cell carcinoma in situ, basal cell carcinoma, papillary thyroid carcinoma, and cervical carcinoma in situ that have undergone radical treatment and do not have any evidence of recurrence).
  8. Patients with uncontrolled anticardiolipin antibody syndrome (APS).
  9. With a history of major organ transplantation (e.g., heart, lung, kidney, and liver) or hematopoietic stem cell/bone marrow transplantation.
  10. Major surgical procedure (craniotomy, thoracotomy, or laparotomy), or unhealed wounds, ulcers, or fractures within 4 weeks prior to screening.
  11. Have received a live/attenuated vaccine within 8 weeks before screening or plan to receive a live/attenuated vaccine during the trial.
  12. Those who are allergic to the study drugs (including ), suffer from severe allergic diseases, or are allergic constitution (such as allergic to two or more drugs, food, or pollen), which may cause damage to the safety of the subjects as judged by the investigator.
  13. Has any of the following cardiac impairment at screening: a. (NYHA) Class III-IV; b. Uncontrolled angina, congestive heart failure, or myocardial infarction within 6 months prior to the first dose; c. prolongation calculated by Fridericia's formula (> 450 msec for males; > 470 msec for females); d. type II second degree atrioventricular (AV) block, third degree atrioventricular (AV) block or PR interval > 250 ms, etc.; e. various factors that may increase the risk of QTcF prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, and unexplained sudden death before 40 years of age in first-degree relatives in family history; f. (LVEF) \< 50%.
  14. Has active or latent tuberculosis infection at screening.
  15. Presence of serious herpes virus infections at screening, such as herpes encephalitis, disseminated herpes, and ophthalmic herpes.
  16. Use of intravenous anti-infectives (including antivirals and antibiotics) for infections within 4 weeks prior to screening.
  17. Has been hospitalized for an opportunistic infection within 3 months prior to screening.
  18. Have been treated with Chinese patent medicines such as Tripterygium wilfordii within 4 weeks before screening.
  19. -positive in hepatitis B panel (HBsAg-negative but HBcAb-positive, additional HBV-DNA quantitative test is required; patients with HBV-DNA test results ≥ the upper limit of reference value at each site or requiring antiviral therapy are ineligible for study participation), antibody-positive (additional HCV-RNA test may be performed; if negative, the patient may be enrolled), Treponema pallidum antibody-positive (if Treponema pallidum antibody is positive, a further Treponema pallidum serological test should be performed; patients who have been infected with syphilis but have been cured as judged by the investigator are eligible), and antibody-positive.
  20. Subjects with significant abnormalities in liver and kidney functions and hematology at screening, including: (ALT) and/or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN), serum total > 1.5 × ULN, \< 90 g/L, white blood cell count \< 3.0 × 10\^9/L, count (PLT) \< 75 × 10\^9/L, and \< 1.0 × 10\^9/L; other abnormal laboratory test results that, in the judgment of the investigator, may affect the subject's completion of the trial or interfere with the trial results.
  21. Dysphagia.
  22. have a history of drug abuse or substance abuse.
  23. Subjects with acute diseases prior to the use of the investigational product. Other conditions judged by the investigator to be unsuitable for enrollment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1 (20 mg, Bid)

    3\~6 subjects will be orally administered with IPD11406 20 mg twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.

    Drug: IPG11406

  • Experimental
    Cohort 2 (40 mg, Bid)

    After cohort 1 complete 28 days of dosing and evaluation, the Safety Monitoring Committee (SMC) will assess the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available pharmacokinetic (PK) data. Based on SMC approval, 3\~6 subjects will be orally administered 40 mg with IPD11406 twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.

    Drug: IPG11406

  • Experimental
    Cohort 3 (80 mg, Bid)

    After cohort 2 complete 28 days of dosing and evaluation, the Safety Monitoring Committee (SMC) will assess the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available pharmacokinetic (PK) data. Based on SMC approval, 3\~6 subjects will be orally administered 80 mg with IPD11406 twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.

    Drug: IPG11406

Interventions

  • Investigational Medical Products: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage:15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability via assessment of Adverse events

    Grades of AE will be assessed according to CTCAE 5.0

    Time frame: Up to 58 days

  2. Evaluate the safety and tolerability via Respiration rate of Vital Signs

    Changes from baseline, Respiration rate in times per minute

    Time frame: Up to 58 days

  3. Evaluate the safety and tolerability via Heart rate of Vital Signs

    Changes from baseline, Heart rate in beats per minute

    Time frame: Up to 58 days

  4. Evaluate the safety and tolerability via Blood pressure of Vital Signs

    Changes from baseline,Blood pressure in mmHg

    Time frame: Up to 58 days

  5. Evaluate the safety and tolerability via Body temperature of Vital Signs

    Changes from baseline,Body temperature in Celsius degree

    Time frame: Up to 58 days

  6. Evaluating the safety and tolerability from Red blood cell count of Laboratory Examination

    Changes from baseline of Red blood cell count in whole blood is reported in the form of number.

    Time frame: Up to 58 days

  7. Evaluating the safety and tolerability from White blood cell of Laboratory Examination

    Changes from baseline of White blood cell count in whole blood is reported in the form of number.

    Time frame: Up to 58 days

  8. Evaluating the safety and tolerability from lymphocyte count of Laboratory Examination

    Changes from baseline , Lymphocyte count in whole blood is reported in the form of number.

    Time frame: Up to 58 days

  9. Evaluating the safety and tolerability from hemoglobin of Laboratory Examination

    Changes from baseline , Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.

    Time frame: Up to 58 days

  10. Evaluating the safety and tolerability from Laboratory Examination

    Changes from baseline of Laboratory Examination (hematology, clinical chemistry, coagulation, urinalysis)

    Time frame: Up to 58 days

  11. Evaluating the safety and tolerability from Prothrombin time of Laboratory Examination

    Changes from baseline, Prothrombin time (PT) is a screening test for exogenous coagulation factors.

    Time frame: Up to 58 days

  12. Evaluating the safety and tolerability from Activated partial thromboplastin time of Laboratory Examination

    Changes from baseline, Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.

    Time frame: Up to 58 days

  13. Evaluating the safety and tolerability from total bilirubin concentration of Laboratory Examination

    Changes from baseline, Changes of total bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: Up to 58 days

  14. Evaluating the safety and tolerability from direct bilirubin concentratio of Laboratory Examination

    Changes from baseline, Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: Up to 58 days

  15. Evaluating the safety and tolerability from ALT of Laboratory Examination

    Changes from baseline, Changes of ALT concentration (U/L) in serum will be recorded.

    Time frame: Up to 58 days

  16. Evaluating the safety and tolerability from AST of Laboratory Examination

    Changes from baseline, Changes of AST concentration (U/L) in serum will be recorded.

    Time frame: Up to 58 days

  17. Evaluating the safety and tolerability from creatinine concentration of Laboratory Examination

    Changes from baseline, Changes of creatinine concentration (μmol/L) in serum will be recorded.

    Time frame: Up to 58 days

  18. Evaluating the safety and tolerability from triglyceridesconcentration of Laboratory Examination

    Changes from baseline, Changes of triglycerides (TG) concentration (mmol/L) in serum will be recorded.

    Time frame: Up to 58 days

  19. Evaluating the safety and tolerability from urine protein of Laboratory Examination

    Changes from baseline, Changes of urine protein will be examined by qualitative test

    Time frame: Up to 58 days

  20. Evaluating the safety and tolerability from urine pH value of Laboratory Examination

    Changes from baseline, Changes of urine pH value will be recorded.

    Time frame: Up to 58 days

  21. Evaluating the safety and tolerability from ventricular rate of Electrocardiogram

    Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for ventricular rate (beats/min)

    Time frame: Up to 58 days

  22. Evaluating the safety and tolerability from PR interval of Electrocardiogram

    Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for PR interval (ms)

    Time frame: Up to 58 days

  23. Evaluating the safety and tolerability from QRS (ms) of Electrocardiogram

    Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for QRS (ms)

    Time frame: Up to 58 days

  24. Evaluating the safety and tolerability from QTc of Electrocardiogram

    Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for QTc (ms),

    Time frame: Up to 58 days

  25. Evaluate the impact of oral IPG11406 on biomarkers in patients with Lupus Nephritis

    Changes in biomarkers before and after medication administration in patients

    Time frame: Up to 58 days

  26. Evaluate the impact of oral administration of IPG11406 on 24-hour urine protein quantitation of proteinuria and renal function in patients with Lupus Nephritis

    Measure the changes in 24-hour urine protein quantitation before and after medication administration

    Time frame: Up to 58 days

  27. Evaluate the impact of oral administration of IPG11406 on estimated glomerular filtration rate of proteinuria and renal function in patients with Lupus Nephritis

    Measure the changes in estimated glomerular filtration rate (eGFR) calculated using the MDRD formula before and after medication administration

    Time frame: Up to 58 days

  28. Evaluate the impact of oral administration of IPG11406 on ratio of 24-hour urine protein to urine creatinine of proteinuria and renal function in patients with Lupus Nephritis

    Measure the changes in ratio of 24-hour urine protein to urine creatinine before and after medication administration

    Time frame: Up to 58 days

  29. Evaluate the impact of oral administration of IPG11406 on proteinuria and renal function in patients with Lupus Nephritis

    Measure the changes in 24-hour urine protein quantitation, estimated glomerular filtration rate (eGFR) calculated using the MDRD formula, and the ratio of 24-hour urine protein to urine creatinine before and after medication administration

    Time frame: Up to 58 days

Secondary outcomes

  1. Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 in Maximum Plasma Concentration

    PK parameters:Maximum Plasma Concentration \[Cmax\]

    Time frame: Up to 28 days

  2. Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 in Area under the curve

    PK parameters (under food effect): Area Under The Curve (AUC)

    Time frame: Up to 28 days

  3. Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 from clearance at steady state

    PK parameters (under food effect): clearance at steady state (CLss/F)

    Time frame: Up to 28 days

  4. Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 from T1/2

    Elimination half-life (T1/2) after dose

    Time frame: Up to 28 days

  5. Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 in CL by plasma concentration of whole blood sample

    Clearance (CL) after dose

    Time frame: Up to 28 days

  6. Evaluate the preliminary efficacy of oral IPG11406 from peripheral blood T lymphocyte counts and proportion

    Changes in peripheral blood T lymphocyte counts and proportions before and after medication administration

    Time frame: Up to 58 days

  7. Evaluate the preliminary efficacy of oral IPG11406 from Autoantibodies

    Changes in autoantibodies before and after medication administration

    Time frame: Up to 58 days

  8. Evaluate the preliminary efficacy of oral IPG11406 from Relative count of lymphocyte subsets

    Changes in Relative count of lymphocyte subsets before and after medication administration

    Time frame: Up to 58 days

  9. Evaluate the preliminary efficacy of oral IPG11406 from cytokines

    Changes in cytokines before and after medication administration

    Time frame: Up to 58 days

  10. Evaluate the preliminary efficacy of oral IPG11406 from Th1/Th2 detection

    Changes in Th1/Th2 before and after medication administration

    Time frame: Up to 58 days

  11. Evaluate the preliminary efficacy of oral IPG11406 from Routine immunological tests

    Changes in Routine immunological tests before and after medication administration

    Time frame: Up to 58 days

  12. Evaluate the preliminary efficacy of oral IPG11406 in patients with Lupus Nephritis

    Changes in peripheral blood B lymphocyte and T lymphocyte counts and proportions, serum albumin, blood creatinine, blood uric acid, blood urea nitrogen (BUN), white blood cells, blood neutrophils, C-reactive protein, complement C3, complement C4, immunoglobulins (IgG, IgA, IgM, IgE), anti-ds-DNA antibody, anti-nuclear antibody, anti-cardiolipin antibody (A/G/M, IgG, IgM), anti-histone antibody, anti-nucleosome antibody, anti-ribosomal P protein antibody, anti-sm antibody, anti-SSA antibody, IL-6, IL-17, IL-2, IL-1β, IL-10, IFN-α, TNF-α, ferritin, and SLEDAI-2K score before and after medication administration

    Time frame: Up to 58 days

  13. Evaluate the preliminary efficacy of oral IPG11406 from 24-hour urine protein test

    Changes in 24-hour urine protein test before and after medication administration

    Time frame: Up to 58 days

  14. Evaluate the preliminary efficacy of oral IPG11406 from Serum ferritin

    Changes in Serum ferritin before and after medication administration

    Time frame: Up to 58 days

  15. Evaluate the preliminary efficacy of oral IPG11406 from Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K) score

    Changes in SLEDAI-2K score before and after medication administration。 Minimum and Maximum Values: The SLEDAI-2K score ranges from 0 (indicating no disease activity) to a maximum possible score that depends on the specific items being scored. However, in practical clinical use, the maximum score is typically much lower than the theoretical maximum, as not all items will be positive in any given patient. The exact maximum score can vary slightly depending on the specific version of the SLEDAI-2K being used, but it is generally well below 100. In the SLEDAI-2K, higher scores indicate a worse outcome. This is because the scale assigns points based on the presence and severity of various lupus manifestations, such as arthritis, rash, fever, and organ involvement. Therefore, as the score increases, it reflects greater disease activity and potentially more severe disease manifestations.

    Time frame: Up to 58 days

07

Study locations

17 sites
  • The First Affiliated Hospital Of Anhui Medical University
    Hefei, Anhui, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • Fujian Provincial Hospital
    Fuzhou, Fujian, China
  • Sun Yai-sen Memorial Hospital, Sun Yai-sen University
    Guangzhou, Guandong, China
  • Hebei Petro China Central Hospital
    Langfang, Hebei, China
  • Xinxiang Central Hospital
    Xinxiang, Henan, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
  • Wuhan Hospital of Traditional Chinese and Western Medicine
    Wuhan, Hubei, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Nanjing DrumTower Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • Nantong First People's Hospital
    Nantong, Jiangsu, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Shandong Provincial Hospital
    Jinan, Shandong, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Jinhua Municipal Centeral Hospital Medical Group
    Jinhua, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Jun 2026, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 5, 2024
StartActual
Feb 25, 2025
Primary completionActual
Jun 8, 2026
CompletionActual
Jun 8, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06717815
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Feb 25, 2025
Primary completion
Jun 8, 2026
Completion
Jun 8, 2026
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IPG11406

Start the discussion